



Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

2026-02-05

New launches in high-content imaging, detection, and automation help labs accelerate drug discovery workflows from sample to insight

WALTHAM, Mass.--(BUSINESS WIRE)-- **Revvity, Inc.** (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the **Opera Phenix OptIQ™ high-content screening system**, the **EnVision Nexus™ One multimode plate reader**, and the **AssayMate™ workstation**, alongside other recently introduced solutions spanning sample preparation, screening, advanced imaging, and lab automation.

At booth #612, Revvity will showcase an expanded portfolio of integrated workflow solutions designed to support discovery programs from early screening through data-driven decision making. Solutions debuting at SLAS2026 include:

- **Opera Phenix OptIQ high-content screening system:** Designed to reduce bottlenecks in phenotypic screening and advanced cellular analysis, this system enables quantitative imaging across complex biological models, including 3D organoids and organ-on-chip systems. Peak camera quantum efficiency has increased from 60% to 95%, improving image sensitivity and data quality, and the system is equipped with Phenologic.AI image analysis software that now includes new classification capabilities, such as cell cycle analysis, expanding beyond its previous focus on segmentation. Laser-based autofocus has been enhanced to better support multi-layer sample carriers, and a new Harmony™ software building block enables detection of organoids in brightfield image stacks.
- **EnVision Nexus One multimode plate reader:** The newest addition to the EnVision Nexus family, the EnVision Nexus One delivers the trusted sensitivity and reliability of the Envision Nexus platform in a streamlined

single-detector configuration optimized for high-throughput screening environments. Designed to simplify automation and integration while supporting evolving assay needs, the system provides enhanced sensitivity across TRF, Alpha, and luminescence detection. The EnVision Nexus One is powered by intuitive Kaleido™ software with 21 CFR Part 11 compliance tools and offers flexible configuration options to support a wide range of laboratory workflows.

- **AssayMate workstation:** The compact, benchtop AssayMate liquid handler delivers intelligent automation performance for labs of any size. It supports a wide volume range of 3-1000 µL without requiring head changes, using a fixed 8-channel head and gripper configuration. Intelligent features such as pressure-based liquid level detection (PLLD) and built-in workflow error handling—including detection of missing plate lids—enable reliable operation and quick experiment resumption. A reconfigurable recessed deck accommodates optional modules such as heater shakers, heater coolers, and magnetic blocks, while AssayPREP™ software provides a user-friendly, drag-and-drop interface that requires minimal training.

“SLAS2026 marks a key milestone for Revvity with the introduction of new platforms that support the evolving needs of discovery labs,” said Kevin Quick, vice president, platforms, Revvity. “These launches integrate automation, trusted assay technologies, and AI-driven imaging to help customers accelerate results while maintaining data quality.”

For more information on Revvity’s new product launches, demonstrations, and conference activities at SLAS2026, visit booth #612 or [this link](#).

For research use only. Not for use in diagnostic procedures.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2025 revenue of \$2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our [Newsroom](#), [LinkedIn](#), [X](#), [YouTube](#), [Facebook](#) and [Instagram](#).

Investor Relations

Steve Willoughby

steve.willoughby@revvity.com

Media Relations

Chet Murray

(781) 462-5126

chet.murray@revvity.com

Source: Revvity